BioSpace News Archive

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of CVD.

On June 23, 2022, the World Health Organization Director General convened its International Health Regulations Emergency Committee to discuss the multi-country outbreak of monkeypox.

Today, the U.S. Food and Drug Administration issued a proposed rule titled, “Nonprescription Drug Product with an Additional Condition for Nonprescription Use,” which is intended to broaden the range of marketed nonprescription drugs available to consumers, empowering them to self-treat certain common conditions and improving public health.

As part of its expansion of radiation shielding solutions in the Industrial segment for radiopharmaceutical manufacturing, Veritas Medical Solutions recently partnered with NorthStar Medical Radioisotopes to construct a radiation shielded facility for the manufacture of concentrated molybdenum-99.

PANTHERx Rare announces that it has been selected by Biocodex as their new exclusive U.S. pharmacy distribution partner for DIACOMIT® (stiripentol).

Varian, a Siemens Healthineers company, today announced that the U.S. Food and Drug Administration (FDA) granted an Investigational Device Exemption (IDE) to advance Varian’s Flash clinical research program with the FAST-02 (FeAsibility Study of Flash therapy for the Treatment of Symptomatic Bone Metastases) clinical trial.

A team of researchers with the Illinois‐Express Quantum Network have successfully deployed a long-distance quantum network between two U.S. Department of Energy laboratories using local fiber optics.

Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the appointment of an accomplished life sciences executive.

Kovina Therapeutics Inc. announced receipt of a Fast-Track Small Business Technology Transfer (STTR) grant from the National Cancer Institute/NIH.

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announce positive results of the Phase 3 clinical trial of brexpiprazole in the treatment of agitation in patients with Alzheimer’s dementia.